We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

118 hedge funds and large institutions have $1.55B invested in iTeos Therapeutics in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 37 increasing their positions, 24 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,050% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 4

85% more capital invested

Capital invested by funds: $841M → $1.55B (+$712M)

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

54% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 24

53% more funds holding

Funds holding: 77 → 118 (+41)

6.23% more ownership

Funds ownership: 88.47% → 94.71% (+6.2%)

Holders
118
Holders Change
+41
Holders Change %
+53.25%
% of All Funds
1.82%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.11%
New
46
Increased
37
Reduced
24
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$15M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$14.7M
3
State Street
State Street
Massachusetts
+$14.7M
4
CS
Candriam SCA
Luxembourg
+$7.73M
5
Millennium Management
Millennium Management
New York
+$7.57M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$15M
2
MAM
MPM Asset Management
Massachusetts
-$13.5M
3
MB
MPM BioImpact
Massachusetts
-$8.73M
4
Citigroup
Citigroup
New York
-$6.82M
5
SAM
Sectoral Asset Management
Quebec, Canada
-$6.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
101
Metropolitan Life Insurance Company (MetLife)
New York
$281K – – –
Legal & General Group
102
Legal & General Group
United Kingdom
$249K +$124K +3,710 +229%
OWP
103
Old Well Partners
North Carolina
$237K +$170K +5,096 New
Nomura Holdings
104
Nomura Holdings
Japan
$226K +$162K +4,852 New
VEA
105
Virtus ETF Advisers
New York
$205K -$110K -3,319 -43%
Russell Investments Group
106
Russell Investments Group
United Kingdom
$204K +$146K +4,400 New
Lazard Asset Management
107
Lazard Asset Management
New York
$178K +$128K +3,837 New
Royal Bank of Canada
108
Royal Bank of Canada
Ontario, Canada
$158K +$41.5K +1,248 +58%
TRCT
109
Tower Research Capital (TRC)
New York
$101K +$53.5K +1,608 +286%
Nisa Investment Advisors
110
Nisa Investment Advisors
Missouri
$95K +$86.5K +2,600 New
AIP
111
Ameritas Investment Partners
Nebraska
$75K – – –
LC
112
Lindbrook Capital
California
$43K +$31K +930 New
Canada Life
113
Canada Life
Manitoba, Canada
$36K +$26.1K +785 New
Daiwa Securities Group
114
Daiwa Securities Group
Japan
$6K – – –
US Bancorp
115
US Bancorp
Minnesota
$5K – – –
Manulife (Manufacturers Life Insurance)
116
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$499 -$4.53K -136 -1%
6CM
117
683 Capital Management
New York
– -$5.41M -200,413 Closed
MFS
118
Mirabella Financial Services
United Kingdom
– -$386K -14,280 Closed
BFM
119
Boothbay Fund Management
New York
– -$267K -9,888 Closed
PCM
120
Penserra Capital Management
California
– -$21K -805 Closed
SOW
121
State of Wyoming
Wyoming
– -$33 -1 -11%
S
122
SignatureFD
Georgia
– +$166 +5 New
1 2 3 4
5

ITOS Hedge Fund Activity: Q4 2021 in Review

118 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2021, worth a combined $1.55B — up 85% from $841M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new ITOS positions and 4 closed out — a net gain of 42 holders — while 37 added to existing stakes and 24 trimmed.

The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $15M. The largest seller was Artal Group, cutting an estimated $15M.

  • 118 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2021, up from 77 in Q3 2021.
  • Funds reported $1.55B of iTeos Therapeutics stock for Q4 2021, up 85% quarter-over-quarter.
  • 46 funds opened new iTeos Therapeutics positions in Q4 2021 and 4 closed out, a net change of +42 holders.
  • The largest iTeos Therapeutics buyer in Q4 2021 was Octagon Capital Advisors, an estimated $15M added.
  • The largest iTeos Therapeutics seller in Q4 2021 was Artal Group, an estimated $15M sold.

Based on aggregated 13F filings for Q4 2021.